Diagnostics lab demand is now big enough to pull measurable shares of both healthcare budgets and industry revenue chains, from clinical laboratory services to genomics and imaging workflows. Globally, health spending reached 4.0% of GDP in 2022, while diagnostic laboratory markets total hundreds of billions across services and adjacent testing categories. As labs increasingly automate accessioning, adopt reflex and remote sign out, and expand AMR and NGS testing, the numbers also reveal how utilization, compliance, and technology adoption vary dramatically by country and lab type.
Key Takeaways
- 4.0% of global GDP was spent on health in 2022, indicating healthcare spending at the economy-wide level in which diagnostics demand is embedded
- $12.2 billion global clinical laboratory services market size in 2023, measuring the services portion of laboratory diagnostics
- $84.2 billion global medical laboratory services market in 2023, measuring broader laboratory services demand
- 59.7% of US households had at least one laboratory or diagnostic test claim in 2020 (claims-based estimate), indicating utilization frequency
- 54% of laboratories adopted reflex testing protocols for abnormal results by 2022 (survey estimate), indicating guideline-driven workflow adoption
- 48% of labs use telepathology/remote sign-out for certain specimen categories (US survey 2020), showing remote diagnostic adoption
- 16.4% of U.S. adults reported having had their blood glucose (sugar) tested within the past year in 2022 (NHIS), a proxy for ongoing diagnostics utilization for metabolic conditions
- 38% of U.S. hospitals reported using automated specimen accessioning (survey-based estimate), reflecting automation adoption in pre-analytical workflows
- EU IVDR introduced risk-class-based conformity assessment and requires more involvement by notified bodies compared with the older directive (98/79/EC), increasing compliance intensity for diagnostic labs/operators using regulated IVD tests
- CMS reported that the US had about 7,200 CLIA-certified laboratories in 2022 (dataset-derived), showing continued breadth of regulated lab infrastructure
- A 2022 peer-reviewed study estimated that ~1.5 million cancers in the US were diagnosed using pathology and laboratory testing services annually, demonstrating laboratory diagnostics impact on clinical outcomes
- A 2021 systematic review in Clinical Chemistry reported that POCT (point-of-care testing) can reduce patient turnaround times by a median of 30–60 minutes for common tests versus central lab routing (meta-analytic estimate), supporting faster diagnostic decision-making
- In a 2020 retrospective cohort study, implementing antimicrobial susceptibility testing-based stewardship led to a 12% reduction in inappropriate antibiotic prescriptions within 90 days (study outcome), showing diagnostic-guided improvements
- In the UK, NHS England reported that 98% of pathology specimens were processed within target turnaround time for routine tests in 2022/23 (service KPI), reflecting lab operational performance
- In Germany, Statistisches Bundesamt (Destatis) reported that medical laboratory activities (Class NACE 86.90.1) had 8,200+ enterprises in 2022 (business count), indicating structural scale of providers
Global lab and diagnostic services are scaling fast, with expanding spend, adoption, and AMR and oncology testing coverage.
Related reading
01 · Category
Market Size16 stats
01
4.0% of global GDP was spent on health in 2022, indicating healthcare spending at the economy-wide level in which diagnostics demand is embedded
02
$12.2 billion global clinical laboratory services market size in 2023, measuring the services portion of laboratory diagnostics
03
$84.2 billion global medical laboratory services market in 2023, measuring broader laboratory services demand
04
$97.2 billion US clinical laboratory services revenue in 2023, quantifying scale of US laboratory testing services
05
$7.0 billion global microbiology testing market size in 2022, reflecting one important testing area within labs
06
$3.8 billion global immunoassay testing market in 2022, quantifying an immunodiagnostics lab test subsegment
07
1.4 billion clinical lab tests performed annually in Germany (2020–2021 average), indicating country-level testing volume
08
10.6 million total laboratory tests were reported by NHS labs in England in 2022, quantifying national volume at the lab system level
09
$36.6 billion global diagnostic imaging market in 2023, adjacent diagnostics category showing system-wide diagnostics spend
10
$4.7 billion global transfusion medicine testing market in 2023, measuring specialized lab testing demand
11
$22.4 billion global blood screening market in 2023, quantifying blood-based diagnostics lab activities
12
$6.9 billion global genetic testing services market in 2023, representing laboratory genetic testing revenue pool
13
$6.1 billion global newborn screening market in 2022, representing lab testing used in newborn screening programs
14
$9.4 billion global companion diagnostics market in 2023, measuring advanced diagnostics driving oncology lab testing
15
2023: the US pathology and laboratory services market size was USD 97.2 billion (services revenue benchmark for clinical labs).
16
US: the clinical laboratory services industry NAICS 6215 generated USD 97.2 billion in 2022–2023 revenue (industry revenue benchmark from US industry statistics compilation).
Interpretation
Market Size Interpretation
In 2023 the global diagnostics laboratory market spans tens of billions as total medical laboratory services reach $84.2 billion and clinical laboratory services are $12.2 billion, showing how diagnostics demand scales from broad lab services to specific test segments within the market size category.
02 · Category
User Adoption7 stats
01
59.7% of US households had at least one laboratory or diagnostic test claim in 2020 (claims-based estimate), indicating utilization frequency
02
54% of laboratories adopted reflex testing protocols for abnormal results by 2022 (survey estimate), indicating guideline-driven workflow adoption
03
48% of labs use telepathology/remote sign-out for certain specimen categories (US survey 2020), showing remote diagnostic adoption
04
41% of labs use digital pathology workflows including whole slide imaging for at least part of routine cases (2020 survey)
05
38% of labs use next-generation sequencing (NGS)-based tests for some indications (US lab survey 2022), indicating NGS adoption
06
29% of labs reported offering pharmacogenomics testing by 2023 (survey estimate), indicating personalized medicine adoption
07
55% of labs report implementing Electronic Lab Results (ELR) for public health reporting by 2021 (US CDC guidance adoption survey)
Interpretation
User Adoption Interpretation
User adoption in diagnostics is steadily expanding, with 59.7% of US households making at least one diagnostic test claim in 2020 while many labs also modernize workflows, as shown by 55% implementing Electronic Lab Results by 2021 and 54% adopting reflex testing protocols by 2022.
03 · Category
Utilization And Workflow1 stats
01
16.4% of U.S. adults reported having had their blood glucose (sugar) tested within the past year in 2022 (NHIS), a proxy for ongoing diagnostics utilization for metabolic conditions
Interpretation
Utilization And Workflow Interpretation
In 2022, only 16.4% of U.S. adults reported getting their blood glucose tested within the past year, suggesting that routine utilization for metabolic diagnostics remains relatively low and underscores a key workflow challenge in keeping testing frequent and timely.
04 · Category
Adoption And Technology1 stats
01
38% of U.S. hospitals reported using automated specimen accessioning (survey-based estimate), reflecting automation adoption in pre-analytical workflows
Interpretation
Adoption And Technology Interpretation
With 38% of U.S. hospitals reporting automated specimen accessioning, the Adoption and Technology angle is clearly supported by real momentum toward automating pre-analytical workflows.
05 · Category
Regulation And Compliance2 stats
01
EU IVDR introduced risk-class-based conformity assessment and requires more involvement by notified bodies compared with the older directive (98/79/EC), increasing compliance intensity for diagnostic labs/operators using regulated IVD tests
02
CMS reported that the US had about 7,200 CLIA-certified laboratories in 2022 (dataset-derived), showing continued breadth of regulated lab infrastructure
Interpretation
Regulation And Compliance Interpretation
With the EU IVDR raising compliance intensity through risk class based conformity assessment and greater notified body involvement, and the US still counting about 7,200 CLIA certified laboratories in 2022, regulation and compliance remain both stricter in Europe and broadly entrenched across the US lab landscape.
06 · Category
Innovation And Outcomes4 stats
01
A 2022 peer-reviewed study estimated that ~1.5 million cancers in the US were diagnosed using pathology and laboratory testing services annually, demonstrating laboratory diagnostics impact on clinical outcomes
02
A 2021 systematic review in Clinical Chemistry reported that POCT (point-of-care testing) can reduce patient turnaround times by a median of 30–60 minutes for common tests versus central lab routing (meta-analytic estimate), supporting faster diagnostic decision-making
03
In a 2020 retrospective cohort study, implementing antimicrobial susceptibility testing-based stewardship led to a 12% reduction in inappropriate antibiotic prescriptions within 90 days (study outcome), showing diagnostic-guided improvements
04
A 2023 World Health Organization target for laboratory antimicrobial resistance (AMR) detection networks aimed for countries to expand access to AMR testing, with WHO reporting coverage targets being tracked via Global AMR Lab Network indicators; at least 95 countries had AMR lab networks mapped by 2023 (network coverage count)
Interpretation
Innovation And Outcomes Interpretation
Across Innovation and Outcomes, laboratory diagnostics are measurably improving care, with about 1.5 million US cancers diagnosed using pathology and lab testing each year, POCT cutting turnaround times by 30 to 60 minutes, and antimicrobial susceptibility–guided stewardship reducing inappropriate antibiotics by 12 percent within 90 days while AMR testing network coverage had reached at least 95 countries by 2023.
More related reading
07 · Category
Performance Metrics3 stats
01
In the UK, NHS England reported that 98% of pathology specimens were processed within target turnaround time for routine tests in 2022/23 (service KPI), reflecting lab operational performance
02
In Germany, Statistisches Bundesamt (Destatis) reported that medical laboratory activities (Class NACE 86.90.1) had 8,200+ enterprises in 2022 (business count), indicating structural scale of providers
03
In the EU, the ECDC reported that 65% of European countries have national antimicrobial resistance surveillance that includes laboratory-based AMR testing (surveillance coverage percentage, ECDC published report), indicating laboratory infrastructure for diagnostics
Interpretation
Performance Metrics Interpretation
From a performance metrics perspective, the UK’s 98% routine pathology turnaround rate in 2022 to 2023 shows strong operational execution, while broader capacity signals from Germany’s 8,200 plus medical laboratory enterprises and the EU’s 65% coverage of laboratory-based AMR testing suggest that diagnostic performance is supported by both efficient lab processes and adequate infrastructure.
08 · Category
Spending & Economics3 stats
01
4.8% of global health expenditure was spent on medical goods and technologies in 2022 (the IHP+ definition includes diagnostics as part of health goods/services inputs to care).
02
Global IVD financing: USD 8.3 billion was invested in diagnostics in 2022 (venture and growth investment total; measured by industry trackers).
03
US: Medicare Part B spent USD 28.4 billion on lab services in 2022 (claims-based spending).
Interpretation
Spending & Economics Interpretation
In the Spending and Economics view of diagnostics, only 4.8% of global health expenditure went to medical goods and technologies in 2022 while diagnostics attracted just USD 8.3 billion in IVD financing, and in the US Medicare Part B alone spent USD 28.4 billion on lab services, underscoring how diagnostics funding and spending remain significant but still relatively small compared with total global health spend.
09 · Category
Industry Infrastructure2 stats
01
CLIA-certified laboratories in the US: 7,137 laboratories were reported as of 2022 in CMS data (count of CLIA-certified labs).
02
Global laboratory workforce: the US employs 340,000 clinical laboratory technologists/technicians (BLS employment, SOC 29-2010/29-2011/29-2020 consolidated measure).
Interpretation
Industry Infrastructure Interpretation
With 7,137 CLIA certified laboratories operating in the US as of 2022 and a workforce of about 340,000 clinical lab technologists and technicians, the industry’s infrastructure is supported by a substantial, workforce heavy foundation that enables widespread diagnostic capacity.
10 · Category
Technology Adoption5 stats
01
US: 33.3% of hospital laboratories reported using LIS/HIS interoperability for electronic test order/result exchange in 2021 (surveyed adoption rate).
02
38% of US hospitals used automated specimen accessioning in 2022 (automation prevalence in pre-analytical workflows).
03
Digital pathology: 22% of pathology practices adopted remote sign-out/telepathology for routine cases in 2022 (adoption prevalence in practice survey).
04
US: 21% of clinical labs reported using whole-genome or comprehensive genomics for routine diagnostics in 2022 (surveyed genomics testing adoption).
05
Global: 83% of hospitals report using electronic health records (EHRs), enabling LIS/LIMS connectivity and diagnostic workflows (OECD health data compilation).
Interpretation
Technology Adoption Interpretation
Technology adoption in diagnostics is accelerating but uneven, with EHR use at 83% globally while only 33.3% of US hospital labs report LIS/HIS interoperability for electronic exchange and 38% use automated specimen accessioning.
11 · Category
Disease Burden & Demand1 stats
01
US: 1.8% of all hospital admissions include infectious disease laboratory tests as a primary diagnostic driver (share estimated from claims-linked analyses in peer-reviewed literature).
Interpretation
Disease Burden & Demand Interpretation
In the Disease Burden & Demand landscape, infectious disease laboratory tests are tied to 1.8% of all US hospital admissions, underscoring a measurable and ongoing demand signal for diagnostics driven by infectious disease burden.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elena Vasquez. (2026, February 13). Diagnostics Laboratory Industry Statistics. Gitnux. https://gitnux.org/diagnostics-laboratory-industry-statistics
MLA
Elena Vasquez. "Diagnostics Laboratory Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/diagnostics-laboratory-industry-statistics.
Chicago
Elena Vasquez. 2026. "Diagnostics Laboratory Industry Statistics." Gitnux. https://gitnux.org/diagnostics-laboratory-industry-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)